"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Descriptor ID |
D019386
|
MeSH Number(s) |
D02.705.429.500.100
|
Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
1999 | 1 | 1 | 2 |
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2009 | 0 | 2 | 2 |
2010 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug; 70(8):1844-53.
-
Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg. 2010 Mar; 68(3):508-14.
-
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb; 68(2):243-53.
-
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul; 67(7):1363-72.
-
Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8.
-
Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women. J Womens Health (Larchmt). 2005 Mar; 14(2):159-71.
-
Early discontinuation of treatment for osteoporosis. Am J Med. 2003 Aug 15; 115(3):209-16.
-
Gastric and duodenal safety of daily alendronate. Arch Intern Med. 2002 Apr 22; 162(8):936-42.
-
Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. J Am Geriatr Soc. 2000 Sep; 48(9):1126-31.
-
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med. 1999 Dec 21; 131(12):935-42.